Longeveron Selects Clinical Research Organization For Phase 2 Alzheimer’s Disease Trial

MIAMI, Nov. 05, 2021 (GLOBE NEWSWIRE) – Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical-stage biotechnology company developing cell therapies for chronic diseases related to aging and putting life threatening, today announced the selection of Biorasi LLC (“Biorasi”) as a Clinical Research Organization (CRO) to help it conduct its Phase 2 clinical trial evaluating the infusion of Lomecel-B in subjects with Alzheimer’s disease (AD).

Biorasi has extensive experience in the management and execution of clinical studies in neurology, with extensive experience in Phase I through IV trials, in the United States and globally.

“Partnering with Biorasi for Longeveron’s upcoming Phase 2 AD trial will help continue to advance the development of Lomecel-B for the treatment of Alzheimer’s disease,” commented Kevin N. Ramdas, MD, MPH, director medical affairs at Longeveron. “We look forward to starting the trial by the end of the year, or in the first quarter of 2022.”

About Longeveron Inc.

Longeveron is a clinical-stage biotechnology company developing cell therapies for specific aging-related and potentially life-threatening conditions. The Company’s primary research product is the LOMECEL-B â„¢ cell therapy product (“Lomecel-B”), which is derived from medicinal signaling cells (MSCs) grown in culture from the bone marrow of young adult donors. in good health. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, he can develop safe and effective therapies for some of the more difficult disorders associated with the aging process and d ‘other life-threatening conditions. Longeveron is conducting clinical research in the following indications / conditions: aging-related frailty, Alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates in pivotal Phase 3 trials, with the goal of obtaining regulatory approvals, subsequent commercialization and wide use by the community. health care. Additional information about the Company is available at www.longeveron.com.

About Biorasi:

Biorasi is an award-winning contract research organization accelerating the clinical development of drugs and devices for life science companies around the world. Since 2002, Biorasi has successfully commercialized innovative therapies by forming true partnerships with sponsors and focusing on the processes, methodologies and technologies that drive the industry forward. Biorasi is headquartered in Miami, Florida, and has regional offices around the world.

Forward-looking and other statements

Certain statements contained in this press release that are not historical facts are forward-looking statements that reflect management’s current expectations, assumptions and estimates regarding future economic performance and conditions, and involve risks and uncertainties that could result in so that actual results differ materially from those anticipated by statements made here. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe”, “expect”, “may”, “”, “provided”, “target”, “see”, ” potential ”,“ estimates ”,“ preliminary ”or“ anticipates ”or the negative thereof or comparable terminology, or by a discussion of the strategy or objectives or other future events, circumstances, or effects. In addition, forward-looking statements contained in this press release include, without limitation, statements about the ability of our clinical trials to demonstrate the safety and efficacy of our product candidates, and other positive results; the timing and direction of our ongoing and future preclinical studies and clinical trials; the size of the market opportunity for our product candidates, the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval for our product candidates, our plans and our ability to obtain or protect intellectual property rights, including extensions of the terms of existing patents when available and our ability to avoid infringing on the intellectual property rights of others. Further information relating to factors that may affect the Company’s results and forward-looking statements is disclosed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than as required by law, to update or revise any forward-looking statement, whatsoever. either because of new information, future events or otherwise.

Brendan Payne
Serious investor relations
Phone. : (212) 362-1200
E-mail: [email protected]

Source: Longeveron Inc
Source: LGVN

Source: Longeveron

Comments are closed.